INTERVIEW WITH PROF. MICHEL DELFORGE
CHALLENGES AND LESSONS LEARNED IN THE MANAGEMENT OF MULTIPLE MYELOMA IN THE SETTING OF COVID-19
Haematologic patients who contract a COVID-19 infection have an overall mortality risk of 34%, according to an international study among patients from 40 countries. The mortality risk of hospitalized haematologic patients with COVID-19 was 39%. Professor dr. Michel Delforge, haematologist from UZ Leuven and specialist on the treatment of Multiple Myeloma discusses the challenges of MM care during the COVID-pandemic… Read more
INTERVIEW WITH MAARTEN VAN HERCK
ALL YOU NEED TO KNOW ABOUT ‘LONG COVID’ AND ITS IMPACT ON HAEMATOLOGICAL AND CANCER PATIENTS
In May 2020, when more and more COVID-19 patients reported a vast array of long lasting symptoms, Hasselt University together with Maastricht University and the Center of Expertise for Chronic Organ Failure (CIRO) was among the first in Europe to investigate this. Now, almost one year later, Van Herck shares his knowledge on what has become known as LONG-COVID... Read more
INTERVIEW WITH CECILE OURY
BSTH’S PRESIDENT CECILE OURY ADVOCATES CONTINUING VACCINATION WITH ASTRAZENECA VACCINE
On April 7, EMA’s safety committee (PRAC) concluded that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine AstraZeneca). So far, almost all clotting incidences in Europe and the UK concerned people under the age of 60, within two weeks of vaccination. However, specific risk factors have not yet been identified… Read more
TOP 3 ARTICLES OF DR. SYLVIA SNAUWAERT
VACCINE-INDUCED PROTHROMBOTIC IMMUNE THROMBOCYTOPENIA FOLLOWING ASTRAZENECA COVID-19 VACCINATION
In our editor’s pick section, a selection of the most relevant literature for your daily practice is presented. In this edition, haematologist Sylvia Snauwaert has selected her top 3 articles in the field of thrombocytopenia following covid-19 vaccinations… Read more
Top
